From Yahoo Finance: 2025-04-15 13:44:00

The US pharmaceutical industry is seeing a rise in acquisitions involving Chinese corporations, with 30% of big pharma deals in 2024 involving Chinese firms, up from 20% the previous year. Chinese companies are gaining attention for their development skills, ability to produce potent compounds, and lower pricing strategies compared to the US.

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) has shown strong financial results, with revenue reaching $731 million in Q4 2024, an 18% increase year-over-year. The company’s revenue for the year was $2.8 billion, up 17% from 2023. Amneal Pharmaceuticals operates in the US, India, and Ireland, focusing on generic and specialty pharmaceutical products like complex generics, injectables, biosimilars, and treatments for CNS and endocrine disorders.

Looking ahead to 2025, Amneal Pharmaceuticals projects revenue between $3.0 to $3.1 billion and an adjusted EBITDA of $650 to $675 million. The company has a strong product pipeline and strategic initiatives, with plans to expand into the weight loss and obesity market through collaborations and launches of new products. Overall, AMRX ranks 9th on the best pharma stocks list for long-term growth.

Investors are bullish on Amneal Pharmaceuticals due to its growth potential and strategic initiatives. The company’s entry into the weight loss and obesity market positions it for long-term success, along with plans to launch new products globally. While pharmaceutical stocks hold promise, AI stocks are seen as offering higher returns within a shorter timeframe. Consider exploring the potential of AI stocks for greater gains.



Read more at Yahoo Finance: Is Amneal Pharmaceuticals, Inc. (AMRX) the Best Pharma Stock to Buy for Long Term Growth?